INTRODUCTION
Surgical resection is the most effective therapy for isolated liver metastases (LM) from colorectal cancer (CRC) ( ) and offers the [1] [2] [3] [4] only possibility of cure in these patients. When complete resection is achieved, 5-year survival rates ranging from 25 41 have been radioimmunotherapy with native or radiolabeled monoclonal antibodies (MAb) based on impressive results in the treatment of non-hodgkin lymphoma ( ). Studies of radiolabeled MAb in the adjuvant setting of CRC or with small volume-disease have been [8] [9] [10] reported ( , ), although success with bulky, metastatic tumors from CRC has been limited ( ). At our institution, an initial phase I 11 12 13-15 study involving patients with non-resectable and chemorefractory LM from colorectal cancer (CRC) showed that the maximal tolerated dose (MTD) of I-anti-CEA F(ab ) was 200 mCi. No patient at this dose level had greater than grade 2 hematologic toxicity (WHO 131 ′ 2 classification), thus alleviating the need for autologous bone-marrow rescue that was observed with a dose of 300 mCi ( ). Based on the 16 results of this study and on the favorable biodistribution showing high tumor uptake of F6 F(ab ) in the majority of the patients with
metastatic CRC, we conducted a phase II study of post-operative radioimmunotherapy (RIT) after complete resection of LM using I F6 131 F(ab ) .
PATIENTS AND METHODS

MAb production and purification
MAb F6 is a murine IgG directed against the Gold-1 CEA-specific epitope ( ). This antibody has undergone extensive preclinical 1a 17
analyses, localization ( ) and therapeutic studies in patients ( ). 18 16
Clinical grade F6 F(ab ) was obtained from Schering-CIS Biointernational (Gif-sur-Yvette, France). It was purified from culture
supernatant by protein A chromatography. F(ab ) was obtained by pepsin digestion and purified by ion-exchange chromatography. The 
Radioiodination of F6 F(ab ) fragments
Radiolabeling was performed by Schering-CIS Biointernational. The diagnostic dose consisted of 5 mg F6 F(ab ) labeled with 8 10 
Patient selection
Patients were eligible if complete resection (R0) of LM from colorectal cancer was deemed possible after assessment by an experienced committee of surgeons, medical and radiation oncologists, and nuclear physicians. Other eligibility criteria included absence of chemotherapy in the six weeks prior to the injection, a serum creatinine concentration less than 120 mol/ml, bilirubinemia less than 30 μ mol/ml, prothrombine time greater than 60 , a platelet count greater than 100.000/mm and a granulocyte count greater than 2000/mm .
μ % 3 3 Patients with severe cardiac, pulmonary or infectious disease, clinical evidence of central nervous system tumor involvement, history of prior administration of mouse-derived antibodies, protein constructs or human antimouse antibody serum reactivity were excluded as were those with a performance status greater than 2 according to the CTC v. 2.0 classification ( ). Patients with prior pelvic radiation therapy 20 could be included. Post-operative chemotherapy was not permitted in the absence of recurrence. The clinical protocol and consent form were approved by our ethical committee and written informed consent was obtained from all patients before study entry. was administered in the form of an i.v. 250 ml isotonic sodium chloride solution in a 60-minute perfusion. The radionuclide doses were not adjusted for body weight or surface area because we believe that individualized calculation of doses should be based on antibody biodistribution and pharmacokinetics rather than body weight or surface area. In the future, we will adjust doses based on data from this trial. Patients were hospitalized in a protected nuclear medecine ward allowing for safe radioactive urine collection and adequate radiation-isolation. Strict radioprotection regulations were reviewed with nursing and auxiliary staff. Visits were forbidden during the entire week. Patients were discharged five to seven days after treatment, depending on the results of dose-rate measurements. They were given recommendations on safety precautions to follow for the next week with the aim of reducing radiation exposure to family members.
Scintigraphic and metabolic monitoring
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The day prior to surgery (four to six days after the I F6 F(ab ) diagnostic dose), 0.08 mCi/kg Tc-sodium phytate (Phytacis ,
CisBio International, Gif-sur-Yvette, France) was administred intravenously to image normal liver and a whole body scan and single photon emission computed tomography (SPECT) were carried out with a Sopha Medical NXT gamma camera and a high-energy, parallel-hole, general purpose collimator. Scintigraphic data was collected through a double isotope acquisition, each with a 20% symmetrical window around 140 keV and 364 keV respectively. SPECT was implemented with a 360 elliptical rotation, 64 projections,°a nd 30s/projection, while slice reconstruction was completed by a Weiner-filtered backprojection technique.
Following the therapeutic dose, complete blood cell counts were performed at least twice weekly until week eight or until the neutrophil and platelet counts returned to normal. Blood chemistry tests and a coagulation profile were done before discharge from the hospital and within four to eight weeks after the therapeutic dose.
Blood samples were collected at the end of the therapeutic injection (t ), at 1, 2, 4, 8 hours post-injection and then once daily until day 0 five. These samples were used to determine the circulating half-lives ( and ) using the biexponential model, and the immunoreactivity of α β the injected F(ab ) fragments as described by Buchegger ( ).
Blood samples were also collected from weeks 3 to 15 to detect the formation of human anti-mouse antibodies (HAMA), using an ELISA assay which provided a quantitive result concerning the anti-isotype human anti-mouse IgG response (HAMA-ELISA, Medac Diagnostika, Hamburg, Germany).
Carcinoembryonic antigen (CEA) values were determined before surgery, before the RIT treatment, every month for the first three months and then every 3 months.
Surgical procedures
Of the 13 patients receiving a therapeutic dose of RIT, 7 underwent a major hepatectomy, 3 underwent a minor hepatectomy, and the remaining 3 patients underwent wedge resections. Major hepatectomy was defined as resection of more than three segments according to the Couinaud classification. Minor hepatectomy was defined as resection of 1 to 3 liver segments. Intraoperative ultrasound was systematically used for complete hepatic evaluation. Postoperative parameters of hepatocyte damage and recovery, including serum transaminase, bilirubin levels and prothrombin time (expressed as a percentage of controls), were measured on postoperative days 1, 2, 5, and 7. Histologic margin to the nearest metastasis was characterized as negative ( 1 cm), close (<1 cm), or positive.
≥
Patient follow-up
All patients underwent a CT of the chest, abdomen, and pelvis before therapy. Follow-up consisted of clinical evaluation with routine blood chemistry, tumor marker dosage (CEA), HAMA production, CT or X-rays of the chest, and CT or ultrasound of the abdomen every three months during the first two years, and then every 6 months for the following 3 years. Clinical and radiologic response were assessed until relapse or death.
RESULTS
Pre-operative imaging and surgery
Twenty-two patients planned for surgery for 1 to 4 LM from colorectal cancer received a diagnostic dose of I-labeled F(ab ) All surgical resections of LM were performed with curative intent at a single institution. Complete resection (R0) was obtained for all 22 patients. Intraoperative ultrasound did not detect LM other than those found by the preoperative staging procedures described above.
No postoperative bleeding or hepatocellular failure was observed.
For one patient ( 6), the suspected LM on pre-operative imaging in segment IV was not palpable intra-operatively after neo-adjuvant # chemotherapy. However, a hyperdense image on intraoperative ultrasound was noted and an immunoscintigraphy of segment IV allowed the visualization of a metastatic nodule (0.7 cm diameter). The patient underwent a metastatectomy of segment VII and a resection of segment IV. This nodule demonstrated an uptake of 34.5 10 ID/g and a metastasis-to-normal liver uptake ratio of 68 ( ).
Anti-CEA F(ab ) uptake in LM and patient selection for therapeutic dose
Metastases and normal liver biopsies obtained during surgery were analyzed for I-F(ab ) uptake by direct radioactivity counting.
131
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All TTL uptake ratios ranged from 1.7 to 32.4, except for one value of 68 as previously discussed ( ). Only patients with ratios Table 1 greater than five were selected for the therapeutic injection. Three other patients ( 7, 12 and 13) that did not meet this criteria also received # inserm-00292535, version 1 -2 Jun 2009 the therapeutic dose. Patient 12 (TTL ratio of 2) was considered to be at high risque of recurrence and no other adjuvant therapy could be offered at that time. Patients 7 and 13 did not receive the pre-operative diagnostic injection but were included because their hepatic recurrence occurred within 1 year of the adjuvant chemotherapy for their primary cancer, and they both refused additional chemotherapy.
It was felt that a post-operative treatment should be offered in the presence of short disease-free intervals, most likely representing aggressive disease. Three other patients with TTL ratios > 5 did not receive the therapeutic dose for various reasons: one had suspected pulmonary metastases and chemotherapy was offered, one died of post-hepatectomy complications and the third had negative SPECT imaging with a bordeline ratio. The treating physician judged that this patient might benefit more from chemotherapy as he was chemotherapy na ve. Clinical characteristics and outcomes of the 13 RIT treated patients are given in .
ï Table 2 Therapeutic injection
The therapeutic injections were performed between day 30 and day 64 after surgery (median 37), depending on each patient s = '
post-operative recovery. All patients presented a postoperative circulating CEA value below 10 ng/ml (which is the upper limit of normal for our CEA assay) except for patient number 2 who had a value of 12 ng/ml. The administered doses ranged from 180 to 200 mCi.
Post-treatment SPECT imaging was negative in all patients.
Pharmacokinetic analysis
Extensive analysis of the radiolabeled F(ab ) serum clearance rates was performed for 12 of the 13 treated patients. This was done shows the kinetic Table 3 parameters and HAMA responses for each of the 13 treated patients.
The immunoreactivity of I-F(ab ) determined from all serum samples was stable for up to 96 h after the injection. It ranged from 70 131 ′ 2 to 100 (median 91 ) of the injected product in the serum of the 11 patients sampled at 72 hours post-injection, and remained in the % % % same range in the 6 patients sampled at 96 hours.
Human anti-mouse antibody (HAMA) response
All 22 patients tested negative for HAMA before the study and they all remained negative after the diagnostic injection. Of the 13 RIT treated patients, 12 were analyzed further for HAMA response. Ten developed HAMA and two patients remained negative until testing was stopped at 15 weeks after RIT ( ). Table 3 Toxicity One patient experienced an allergic reaction to the diagnostic dose. Symptomatic clinical toxicity was mild to moderate (grade 1 or 2) and consisted mostly of fatigue and anorexia, occurring in 61.5 and 23 , respectively. Unexplained fever was observed in one patient % % without concurrent neutropenia. Hematologic toxicity was significant ( ), but there were no toxicity-related deaths. Cytopenic nadirs Table 4 usually occurred between weeks 4 and 6, with recovery by week 6 to 9. No febrile neutropenia was observed and no patient required granulocyte colony-stimulating factor (G-CSF). The grade 4 thrombocytopenias lasted from 9 to 33 days. No patient experienced symptomatic bleeding and only one patient ( 6) required platelet transfusions. # Patient 2 presented no toxicity at all which may be related to the short mean residual time observed (37 h 45 min). Two other patients ( 3 and 9) experienced no leukocyte toxicity despite grade 4 thrombopenia. There was no correlation to the MRT of the therapeutic # injection (52 h 54 min and 43 h 34 min, respectively).
Patient follow-up
At the time of writing, with 127 months of median follow-up, 2 of the 13 treated patients are still alive. Median DFS was 12 months and median OS was 50 months. 
DISCUSSION
Over the past two decades, RIT has made important progress in cancer treatment, particularly in radiosensitive lymphomas where two biologically different radiopharmaceutical agents targeting CD20 surface antigen have demonstrated clinical safety and efficacy ( , ).
Both Y-ibritumomab tiuxetan and I-tositumomab have shown impressive overall response rates and complete response rates in 90 131 patients with relapsed, refractory or transformed CD20 indolent B-cell lymphoma.
+
The natural radiosensitivity of lymphomas make them ideal tumors for this treatment when given as a single agent and may explain in part why similar success has not been obtained with solid, bulky malignancies, notably in CRC ( ). Other explanations may include 13-15 the more heterogeneous antigen expression and density of solid tumors or factors that limit agent delivery such as: location in solid organs or on peritoneal surfaces, heterogeneous tumor vascularity or slow diffusion of Abs to tumoral tissues ( , ). Furthermore, it has been 22 23
shown in solid tumors that MAb uptake and the resulting radiation doses are inversely correlated with tumor size ( , ). Uptake is also 13 18 higher in the periphery of the tumor than at its core ( ). Hence, microscopic disease is probably more suited for RIT and clinical benefit 18 might be observed only in the presence of smaller tumor burden. Behr tested this hypothesis in 19 metastatic CRC patients with et al.
small-volume disease. All lesions were smaller than three cm and patients received 60 mCi/m of I-hMN14, a humanized anti-CEA 2 131 antibody ( ). Partial response rate of 16 were reported and the overall response rate was 58 . In the same study, 9 other patients were 11
% % treated post-operatively after surgical resection of LM and 7 of these remained disease-free for up to 36 months. Transient myelosuppression was the only toxicity observed.
The present study is a phase II trial of radioimmunotherapy in which the feasibility and toxicity of high dose I F6 F(ab ) after We cannot draw conclusions as to the efficacy of this treatment since this was not taken into account during the design of our phase II study. However, median OS (50 months) and DFS (12 months) are provided for information and seem to be comparable to historical controls despite the small number of patients, which included 2 patients with metastases at the time of treatment.
Although much effort has been put into investigating peri-operative treatment to improve the outcome of these patients, there is no According to clinical dosimetric data obtained in a previous study, the maximum delivered dose to LM can be estimated as being 10
Gy per 100 mCi of injected I-F6 F(ab ) ( ). This is insufficient to eradicate macroscopic metastases (which require at least 50 to 70 131 ′ 2 18 Gy), or even to eradicate microscopic disease. One strategy to improve the results of RIT in CRC would be repeated administration of anti-tumor radiolabeled Mab in order to increase the cumulative dose. This could be done using humanized Ab to avoid HAMA formation in response to repeated injection of murine Ab. A limitation of this approach is the need to wait at least 2 or 3 months to allow full bone marrow recovery before delivering a second therapeutic dose. However, this opens the possibility of tumor cell repopulation during this relatively long waiting period. Another option would be to combine RIT with chemotherapy which could also act as a radiosensitizer, but cumulative hematologic toxicity is of concern. Wong conducted a phase I dose-escalation study of Y-anti-CEA chimeric T84.66 et al. 
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There is only one other published trial delivering RIT to metastatic CRC patients in the post-operative setting ( ). In this phase II 12 trial, Liersch treated 23 patients who underwent hepatectomies for LM of CRC with 40 60mCi/m of I-labetuzumab, a humanized et al. anti-CEA IgG2 has been developped at our center and is a promising candidate for RIT in intact form, as a F(ab ) , or as a bispecific
antibody ( ). Other promising avenues include use of affinity enhancement systems with pre-targeting bispecific MAb ( ). 33 34 In conclusion, this phase II study demonstrates that RIT after complete resection of LM in CRC is both feasible and well tolerated.
These findings support those of others and suggest that RIT, either alone with surgery or in a multimodality setting including chemotherapy, should be evaluated in a randomized trial.
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